Association between high dietary intake of the \(n-3\) polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn’s disease

S. S. M. Chan*†, R. Luben‡, A. Olsen§, A. Tjonneland‖, R. Kaaks‖, S. Lindgren**, O. Grip**, M. M. Bergmann‡‡, H. Boeing‡‡, G. Hallmans‡‡, P. Karling§§, K. Overvad¶¶, S. K. Venø***, F. van Schaik†††, B. Bueno-de-Mesquita†††,‡‡‡,§§§, B. Oldenburg†††, K.-T. Khaw‡, E. Riboli¶¶¶ & A. R. Hart*†

*Department of Medicine, Norwich Medical School University of East Anglia, Norwich, UK.
†Norfolk & Norwich University Hospitals NHS Trust, Norwich, UK.
‡Strangeways Research Laboratory, Institute of Public Health, University of Cambridge, Cambridge, UK.
§Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark.
‖Division of Clinical Epidemiology, DKFZ-German Cancer Research Centre, Heidelberg, Germany.
**Department of Clinical Sciences, University Hospital, Malmö, Sweden.
††Department of Epidemiology, German Institute of Human Nutrition, Potsdam, Germany.
§§Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden.
¶¶Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark.
***Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
****Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.
†††National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
§§§The School of Public Health, Imperial College London, London, UK.
¶¶¶Division of Epidemiology, Imperial College London, London, UK.

Correspondence to:
Dr S. S. M. Chan, Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
E-mail: simon.chan@uea.ac.uk

Publication data
Submitted 25 October 2013
First decision 18 November 2013
Resubmitted 16 January 2014
Accepted 30 January 2014
EV Pub Online 24 February 2014

This article was accepted for publication after full peer-review.

SUMMARY

Background
There are plausible mechanisms for how dietary docosahexaenoic acid (DHA), an \(n-3\) polyunsaturated fatty acid, could prevent Crohn’s disease (CD).

Aim
To conduct a prospective study to investigate the association between increased intake of DHA and risk of CD.

Methods
Overall, 229,702 participants were recruited from nine European centres between 1991 and 1998. At recruitment, dietary intakes of DHA and fatty acids were measured using validated food frequency questionnaires. The cohort was monitored through to June 2004 to identify participants who developed incident CD. In a nested case–control analysis, each case was matched with four controls; odds ratios (ORs) were calculated for quintiles of DHA intake, adjusted for total energy intake, smoking, other dietary fatty acids, dietary vitamin D and body mass index.

Results
Seventy-three participants developed incident CD. All higher quintiles of DHA intake were inversely associated with development of CD; the highest quintile had the greatest effect size (OR = 0.07; 95% CI = 0.02–0.81). The OR trend across quintiles of DHA was 0.54 (95% CI = 0.30–0.99, \(P_{\text{trend}} = 0.04\)). Including BMI in the multivariate analysis, due to its correlation with dietary fat showed similar associations. There were no associations with the other dietary fatty acids studied.

Conclusion
There were inverse associations, with a biological gradient between increasing dietary docosahexaenoic acid intakes and incident Crohn’s disease. Further studies in other populations should measure docosahexaenoic acid to determine if the association is consistent and the hypothesis tested in randomised controlled trials of purely docosahexaenoic acid supplementation.

Aliment Pharmacol Ther 2014; 39: 834–842

© 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
doi:10.1111/apt.12670
INTRODUCTION

Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) of unknown aetiology that can affect any part of the gastrointestinal tract. Patients often have a lifelong morbidity from debilitating symptoms, require surgery and have an increased risk of intestinal failure. While genomic wide association studies have identified over 140 genetic risk loci for CD,1 the risk contribution from these is estimated to be less than 25%.2 This implies that other exposures such as environmental/lifestyle variables, including diet may be involved in CD aetiology.3

The long chain dietary n-3 polyunsaturated fatty acids (PUFAs), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) may be involved in the aetiology of CD, given the importance of PUFAs in the regulation of immunological and inflammatory responses.4 These n-3 PUFAs inhibit genes that activate the inflammatory process5 and alter the composition of cell membranes influencing lipid raft formation in cell signalling.6 Furthermore, long chain n-3 PUFAs are metabolised to lipid mediators with weaker pro-inflammatory properties compared to those derived from n-6 PUFAs.7 More recently, emerging evidence reports that DHA and EPA can also be metabolised to lipid mediators with anti-inflammatory and inflammation resolving properties.8

Despite the experimental evidence implying biological plausibility, epidemiological studies investigating associations between dietary intakes of n-3 PUFAs and CD aetiology are sparse. These are mainly retrospective case–control studies,9 and a single prospective investigation which reported the risk of developing CD was unaffected by total n-3 PUFAs and long chain n-3 PUFAs intakes.10 However, the effects of specific individual long chain n-3 PUFAs, DHA and EPA were not investigated. This is important as the biological effects of these long chain n-3 PUFAs and their metabolites are not uniform with them acting via both distinct and shared pathways.11, 12 Accordingly, we performed this nested case–control analysis within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort investigating the effect of individual long chain n-3 PUFAs in CD. Demonstrating associations would imply that the dietary intake of specific n-3 PUFAs should be measured in future aetiological studies of CD.

METHODS

The methods of the main EPIC cohort study have been previously described.13 This analysis of CD is a sub-cohort of 229 702 initially healthy men and women without CD, aged 20–74 years. Participants were resident in nine European regions, enrolled between 1991 and 1998 (Table I). Baseline questionnaires were self-completed by participants who supplied information on age, gender, smoking (nonsmoker, ex-smoker or smoker at recruitment) and diet. Body mass indexes (BMI) were calculated from participants’ weight and height at baseline recruitment.14 Habitual diet over the previous year was measured using validated country-specific food frequency questionnaires (FFQs) consisting of approximately 200 food items and nine frequency categories of intake. Using national databases of food composition, the daily intakes of total fat, DHA (n-3 PUFA), EPA (n-3 PUFA), α-linolenic acid (ALA, n-3 PUFA), linoleic acid (LA, n-6 PUFA) and oleic acid (OA, n-9 monounsaturated fatty acid, MUFA), total energy intake and dietary vitamin D were calculated. In all centres, the FFQs were validated against 24-h recall questionnaires and biomarkers for specific nutrients.15 Intakes of ALA were recorded as this is converted to EPA and DHA.16 LA and OA intakes were recorded as these increase17 and decrease18 arachidonic acid mucosal concentrations, respectively, which may be involved in the inflammatory process. Dietary vitamin D was recorded as this is found in similar foods as long chain n-3 PUFAs and is associated with a reduced risk of CD.19

The cohort was monitored after recruitment until June 2004 to identify initially well participants who developed a new diagnosis of CD. National disease and regional IBD registries, follow-up questionnaires, in-patient records and histology databases were used for case identification. Medical notes of potential cases were reviewed by local gastroenterologists to confirm diagnoses and acquire information on diagnostic investigations and disease extent. Cases of indeterminate or microscopic colitis were excluded. Those with prevalent IBD at recruitment were excluded, as were participants diagnosed with IBD <18 months after recruitment, to ensure data reflected diet prior to symptoms and diagnosis.

In a nested case–control analysis, each case was matched with four randomly selected controls matched for age at recruitment (±6 months), gender, centre and recruitment date (±3 months). Controls had to be alive on the date of diagnosis of their matched case. None of the controls had ulcerative colitis, microscopic or indeterminate colitis. Intakes of each fatty acid, total energy and vitamin D were divided into quintiles, according to the distribution across the cohort. BMI was divided into four categories (<20 kg/m², 20–24.9 kg/m², 25–29.9 kg/m², ≥30 kg/m²). Baseline characteristics between cases and
controls were compared using a t-test for parametric distributions, a Mann–Whitney test for nonparametric ones and the χ²-test for categorical ones. Odds ratios (OR) with 95% confidence intervals (CI) were calculated using conditional logistic regression (STATA version 11) for total fat, combined long chain n–3 PUFAs (DHA and EPA) and each individual dietary fatty acid and the development of CD, adjusted for the covariates of cigarette smoking and total energy intake. In a second analysis, total fat and combined long chain n–3 PUFAs were adjusted for individual relevant fatty acids due to their differing effects on the inflammatory process and interdependent metabolism, covariates in the first model and dietary vitamin D. Similar analyses were used to calculate OR for individual dietary fatty acids, adjusting for the other fatty acids that influence fatty acid metabolism and have opposing effects on inflammation. A further analysis included all the covariates from the second model plus BMI to decrease the risk of residual confounding from the likely correlation between dietary fat and BMI. OR trends were calculated across quintiles using the score 1–n, with n corresponding to quintiles 1–5 treated as continuous. In a sensitivity analysis, both the lowest and highest 2.5% of dietary nutrients were excluded as some participants may under or over report their intake. A further sensitivity analysis calculated ORs excluding those who developed CD within 3 years and 5 years after recruitment to assess if fatty acid intake is related to the time prior to diagnosis. Research protocols were approved by local ethics committees. All subjects gave written informed consent for access to their data.

RESULTS

A total of 73 participants developed CD (64% female) at a median age of 56.4 years (Table 2) with median time of diagnosis 5.3 years after recruitment. This equates to an appropriate incidence of 4/100 000 per year based on the size and follow-up times of each sub-cohort. Of those with CD, 29% had ileal disease only and 42% had colonic disease only. Cigarette smoking was positively associated with CD (OR = 2.40, 95% CI = 1.16–4.94; P = 0.02). The FFQ data on PUFAs were complete for 100% of cases and 99% of controls, with no significant differences between cases and controls between the median daily total energy and fatty acids (Table 2).

In the multivariate analysis, no differences were observed in the odds of CD across quintiles of total fat or combined long chain n–3 PUFAs (DHA and EPA)
intake (Table 3). For individual fatty acids, adjusted for smoking and total energy intake, there were no statistically significant associations across quintiles of dietary DHA, EPA, LA, ALA or OA, although those for DHA were all less than one (Table 4). In a second analysis, including other fatty acids and dietary vitamin D, compared with the lowest quintile, all four of the higher quintiles of DHA had a reduced odds of CD, with the greatest reduction in the highest quintile (OR = 0.07, 95% CI = 0.02–0.81). There was a biological gradient across quintiles of DHA (OR\textsubscript{trend} = 0.54, 95% CI = 0.28–0.96, \textit{P}\textsubscript{trend} = 0.04) or the other dietary fatty acids. The numbers according to disease site were small, but the trends across quintiles of DHA did not show any significant associations for terminal ileal or colonic disease. Excluding the lowest 2.5% and highest 2.5% of all nutrient intakes gave similar results for the highest quintile of DHA intake (OR = 0.03, 95% CI = 0.01–0.96) in the model containing all covariates. The possibility of reverse causation bias, with symptoms prior to diagnosis influencing DHA intake was also considered. However, the magnitude of the trends across quintiles for DHA were similar in the third model when excluding those diagnosed within 3 years (OR\textsubscript{trend} = 0.49, 95% CI = 0.24–1.04, \textit{P}\textsubscript{trend} = 0.06) and within 5 years (OR\textsubscript{trend} = 0.37, 95% CI = 0.13–1.07, \textit{P}\textsubscript{trend} = 0.07) of recruitment. This process excluded 16 and 32 cases, respectively.

CONCLUSIONS

The main finding of this study was a statistically significant inverse association between the development of incident CD and the dietary intake of the long chain \textit{n}–3 PUFA, DHA. The highest quintile of DHA was associated with a reduction in the odds of developing incident CD of 94%, the equivalent of eating one to two portions of oily fish per week. The data suggest that long-term DHA intake may be important as the effect sizes were similar across varying time periods before diagnosis. Evidences to support a true aetiological association with DHA are: plausible biological mechanisms, a large effect size and a biological gradient with increasing DHA dietary intakes. Mechanistic studies suggest that the anti-inflammatory properties of DHA may be partly mediated via competitive inhibition of arachidonic acid metabolism,\textsuperscript{20, 21} which is required for the production of pro-inflammatory lipid derived mediators (eicosa-

### Table 2 | Characteristics of cases and controls

|                                      | Controls (\textit{n} = 292) | Cases (\textit{n} = 73) |
|--------------------------------------|-----------------------------|-------------------------|
| Age at recruitment (years, median and range) | 50.2 (29.1–75.8)            | 50.5 (29.4–75.8)         |
| Gender (% female)                    | 64%                         | 64%                     |
| Age at diagnosis (years, median and range) | --                          | 56.4 (24.0–78.7)         |
| Time between recruitment & diagnosis (years, median and range) | --                          | 5.3 (1.5–14.3)           |
| Distribution of disease (\textit{n}, %)                                      |
| L1, ileal                            | 21 (29%)                    |                         |
| L2, colonic                          | 31 (42%)                    |                         |
| L3, ileocolonic                      | 14 (19%)                    |                         |
| L4, isolated upper GI disease        | 2 (3%)                      |                         |
| Current smoker                       | 27%                         | 40%*                    |
| Total energy intake (kJ/day, median and range) | 8486 (3684–19 722)          | 8711 (4509–18 056)       |
| Body mass index (kg/m\textsuperscript{2}) (mean, s.d.) | 25.1 (3.7)                 | 25.1 (4.0)               |
| Median daily intakes (g/day, range)  |
| Docosahexaenoic acid                 | 0.13 (0.01–1.49)            | 0.14 (0.02–0.97)         |
| Eicosapentaenoic acid                | 0.07 (0.01–0.82)            | 0.06 (0.01–0.63)         |
| \textit{α}-linolenic acid            | 1.30 (0.40–4.51)            | 1.33 (0.68–5.14)         |
| Linoleic acid                        | 10.33 (3.12–39.71)          | 10.60 (4.08–44.19)       |
| Oleic acid                           | 21.01 (6.05–76.75)          | 22.55 (10.18–62.28)      |

Cases were more likely than controls to be smokers.

* \textit{P} < 0.05.
Table 3 | Dietary fats and the odds of Crohn’s disease

| Quintiles, g/day | Controls (n = 290, %) | Cases (n = 73, %) | OR (95% CI)* | OR (95% CI)† | OR (95% CI)‡ |
|------------------|-----------------------|------------------|--------------|--------------|--------------|
| Total fat        |                       |                  |              |              |              |
| 24.4–55.7        | 61 (21.0%)            | 12 (16.4%)       | 1.00         | 1.00         | 1.00         |
| 55.7–68.9        | 60 (20.7%)            | 13 (17.8%)       | 1.18 (0.44–3.13) | 1.18 (0.43–3.21) | 1.20 (0.43–3.35) |
| 68.9–86.9        | 59 (20.3%)            | 13 (17.8%)       | 1.37 (0.41–4.63) | 1.31 (0.38–4.55) | 1.40 (0.40–4.97) |
| 87.6–106.7       | 52 (17.9%)            | 21 (28.8%)       | 2.93 (0.82–10.50) | 2.68 (0.71–10.10) | 2.74 (0.71–10.51) |
| 107.3–221.1      | 58 (20.0%)            | 14 (19.2%)       | 1.59 (0.33–7.59) | 1.48 (0.28–7.73) | 1.42 (0.26–7.67) |

P\textsubscript{trend} = 0.25 P\textsubscript{trend} = 0.32 P\textsubscript{trend} = 0.33

| Combined long chain fatty acids (DHA and EPA) | Controls (n = 290, %) | Cases (n = 73, %) | OR (95% CI)* | OR (95% CI)† | OR (95% CI)‡ |
|-----------------------------------------------|-----------------------|------------------|--------------|--------------|--------------|
| 0.01–0.09                                     | 56 (19.3%)            | 17 (23.3%)       | 1.00         | 1.00         | 1.00         |
| 0.09–0.17                                     | 59 (20.4%)            | 13 (17.8%)       | 0.65 (0.27–1.57) | 0.56 (0.21–1.48) | 0.55 (0.21–1.47) |
| 0.17–0.25                                     | 60 (20.8%)            | 13 (17.8%)       | 0.64 (0.26–1.57) | 0.51 (0.19–1.43) | 0.52 (0.19–1.43) |
| 0.26–0.48                                     | 60 (20.8%)            | 12 (16.4%)       | 0.66 (0.24–1.80) | 0.54 (0.17–1.72) | 0.56 (0.18–1.76) |
| 0.48–2.15                                     | 54 (18.7%)            | 18 (24.7%)       | 1.19 (0.40–3.57) | 1.03 (0.28–3.85) | 1.08 (0.29–4.11) |

P\textsubscript{trend} = 0.89 P\textsubscript{trend} = 0.84 P\textsubscript{trend} = 0.87

* Adjusted for smoking and total energy intake.
† Covariates in analysis 1 plus dietary vitamin D and relevant fatty acids (total fat unadjusted for individual fatty acids; total DHA and EPA adjusted for ALA, LA, OA; saturated fat adjusted for DHA, EPA, ALA, LA and OA).
‡ Covariates in analysis 2 and BMI.

These include leukotrienes and prostaglandins that are present in increased amounts in the mucosa of patients with CD. DHA also inhibits key transcription factors such as PPAR\textgamma and NFkB, required for the intracellular signalling cascade that activates inflammation. More recently, studies have reported that DHA is metabolised to resolvins, lipid mediators with both anti-inflammatory and inflammation resolving properties. These may have a role in CD aetiology as resolvins prevent gastrointestinal inflammation in murine models of CD. For EPA, the lack of inverse associations, but nonstatistically significant positive ORs were completely unexpected, as experimental work has reported that EPA is metabolised to lipid mediators with similar anti-inflammatory properties to DHA.

The inverse association between DHA and CD was only observed following adjustment for fatty acids and vitamin D that could all potentially influence the biological effects of DHA and EPA. Adjustments were performed as the different fatty acids influence firstly the metabolism of each other and secondly the inflammatory pathway itself. As described earlier, dietary ALA is converted to EPA and DHA, while LA and OA increase and decrease mucosal arachidonic acid concentrations, respectively, which is metabolised to pro-inflammatory mediators. The fact that combined long chain n–3 PUFAs (DHA and EPA) did not affect the odds of CD is consistent with the only other prospective analysis performed in the exclusively female Nurses’ Health Study Cohort, which did not investigate individual long chain n–3 PUFAs. To the best of our knowledge, our study is the first prospective study of CD investigating DHA and EPA.
EPA separately, which warrants confirmation in other populations.

Evidence supporting a beneficial effect of DHA in preventing CD would be provided from randomised controlled trials (RCTs) of DHA supplementation in the general population investigating if this reduced incidence. Clearly, these are impractical due to the large number of participants needed to accrue sufficient cases. DHA in the form of fish oil supplementation has been assessed in RCTs of preventing relapse in patients with CD,\textsuperscript{30, 31} although subsequent meta-analyses reported little benefit.\textsuperscript{32} This may be as a consequence of \textit{n}–\textit{3} PU-FAs having different roles in CD aetiology compared to the natural history in patients with established disease. Alternatively, given that fish oil supplements contains both DHA and EPA, which may have different biological effects, perhaps dietary interventions should focus on increasing just DHA intake alone.

Our study methodology had several strengths including the prospective collection of dietary information which minimised recall biases. Selection biases were reduced as cases and controls were drawn from the same population investigating if this reduced incidence. Clearly, these are impractical due to the large number of participants needed to accrue sufficient cases. DHA in the form of fish oil supplementation has been assessed in RCTs of preventing relapse in patients with CD,\textsuperscript{30, 31} although subsequent meta-analyses reported little benefit.\textsuperscript{32} This may be as a consequence of \textit{n}–\textit{3} PU-FAs having different roles in CD aetiology compared to the natural history in patients with established disease. Alternatively, given that fish oil supplements contains both DHA and EPA, which may have different biological effects, perhaps dietary interventions should focus on increasing just DHA intake alone.

Our study methodology had several strengths including the prospective collection of dietary information which minimised recall biases. Selection biases were reduced as cases and controls were drawn from the same population investigating if this reduced incidence. Clearly, these are impractical due to the large number of participants needed to accrue sufficient cases. DHA in the form of fish oil supplementation has been assessed in RCTs of preventing relapse in patients with CD,\textsuperscript{30, 31} although subsequent meta-analyses reported little benefit.\textsuperscript{32} This may be as a consequence of \textit{n}–\textit{3} PU-FAs having different roles in CD aetiology compared to the natural history in patients with established disease. Alternatively, given that fish oil supplements contains both DHA and EPA, which may have different biological effects, perhaps dietary interventions should focus on increasing just DHA intake alone.

Our study methodology had several strengths including the prospective collection of dietary information which minimised recall biases. Selection biases were reduced as cases and controls were drawn from the same population investigating if this reduced incidence. Clearly, these are impractical due to the large number of participants needed to accrue sufficient cases. DHA in the form of fish oil supplementation has been assessed in RCTs of preventing relapse in patients with CD,\textsuperscript{30, 31} although subsequent meta-analyses reported little benefit.\textsuperscript{32} This may be as a consequence of \textit{n}–\textit{3} PU-FAs having different roles in CD aetiology compared to the natural history in patients with established disease. Alternatively, given that fish oil supplements contains both DHA and EPA, which may have different biological effects, perhaps dietary interventions should focus on increasing just DHA intake alone.

Our study methodology had several strengths including the prospective collection of dietary information which minimised recall biases. Selection biases were reduced as cases and controls were drawn from the same population investigating if this reduced incidence. Clearly, these are impractical due to the large number of participants needed to accrue sufficient cases. DHA in the form of fish oil supplementation has been assessed in RCTs of preventing relapse in patients with CD,\textsuperscript{30, 31} although subsequent meta-analyses reported little benefit.\textsuperscript{32} This may be as a consequence of \textit{n}–\textit{3} PU-FAs having different roles in CD aetiology compared to the natural history in patients with established disease. Alternatively, given that fish oil supplements contains both DHA and EPA, which may have different biological effects, perhaps dietary interventions should focus on increasing just DHA intake alone.
population. We considered the potential confounding effect of smoking, but had no information on other co-

variates such as family history of CD or appendicectomy. Residual confounding is a possibility if DHA is a marker for another, possibly dietary exposure, which is actually the true aetiological factor. However, including dietary vitamin D in our models, which is found in similar foods to longer chain n−3 PUFAs, and BMI, did not change our results. Similarly, the effect sizes were unaffected when adjustments for linoleic acid (n-6 PUFA) were excluded suggesting that the effects of low DHA intake were not as a consequence of higher n-6 intakes. Other aetiological hypotheses will be explored in future work and DHA adjusted for any associations. Aspects of our study are generalizable in that our cohort included both genders recruited from several countries with the number developing CD approximately similar to that expected from data in a large European study of IBD incidence.33 The anatomical distribution of CD is proba-

bly explained by the older age of our cohort as these patients are more likely to develop colonic disease.34 We recruited mainly middle aged to elderly participants and so were unable to ascertain if our findings apply to younger people. However, UK studies reporting that consumption of oily fish, a marker of DHA intake is up to 30% lower in those aged 19–64 years, compared to older people.35 Therefore, the benefits of increasing DHA intake may be greater in younger persons. A limita-

tion is measurement error inherent in the FFQs for recording habitual diet. Although FFQs are pragmatic to use in large epidemiological studies, they are less accu-

rate than either food diaries or weighed records.36 Fur-

thermore, we only had one measure of diet at recruitment, although it has been reported that diet remains relatively stable over time in adults in terms of categories of nutrient intake.37 Both these sources of measurement error would result in an underestimate of effect sizes rather than a spurious overestimate. A fur-

ther limitation is the number of CD cases in our study may mean that smaller dietary associations would be undetected.

Finally, our statistical analysis, namely adjusting for all the fatty acids, has both strengths and limitations. The analysis was an a priori one, which we decided was important as fatty acids can firstly influence the inflammatory process in different ways and secondly affect the metabolism of each other. Therefore, failure to consider each one in the analysis could mean effects went undetected or were spuriously exaggerated. However, we acknowledge that adjusting for multiple nutrients can introduce statistical instability leading to imprecise measures of the effect sizes. Furthermore, including several factors in a model correlated with each other, as occurred for DHA and EPA (r = 0.95), can result in collinearity, although as discussed previ-

ously, there were some differences in the food sources of these. This phenomenon may introduce spurious inaccurate estimates of the individual effect sizes, although the predictivity of the model as a whole remains accurate. If collinearity is the explanation, then in our adjusted analysis, this means that the effect of DHA is dependent on the other fatty acids included. Despite the possibility of collinearity, evidence for a true effect of DHA are: a plausible biological mecha-

nism supported by the inverse direction of the associa-

tions, a dose–response effect, and in the model which excluded other fatty acids, the associations for quintiles were all in the same direction as the model in which they were included. Whether the inverse association with DHA is real, can only be clarified in randomised controlled trials in participants who are given purely DHA supplementation. Importantly, additional EPA should not be administered in view of the suggestive positive trend we observed and as previous trials of fish oil supplementation,31, 32 which contained both DHA and EPA did not report any clinical benefit.

In conclusion, we report an inverse association between higher intakes of dietary DHA and the develop-

ment of CD. Evidence for a causal association is sup-

ported by plausible biological mechanisms, large effect sizes and a possible dose–response relationship. To con-

firm causality, consistent findings are needed from other populations and laboratory studies on potential biological mechanisms. While appreciating that DHA may play dif-

ferent roles in CD aetiology and treatment, the hypothe-

sis of a protective effect of DHA would be supported by good quality interventional studies of DHA specifically in treating relapses in patients. These trials would assess the effect of the dose and timing of DHA administered, compared to appropriate placebos, and would also remove the potential problem of collinearity which can exist in observational studies. Such work is important, for if our findings are consistent then the incidence of CD may be reduced by dietary modifications and inter-

ventions.

**AUTHORSHIP**

Guarantor of the article: Simon Chan.

Author contributions: SSMC and ARH designed the study, recruited the centres, analysed the data and wrote
We thank the EPIC participants in this study. The Sir Halley Stewart Trust, Crohn’s and Colitis UK and The NHS Executive Eastern Region. SSMC is supported by an NIHR clinical lectureship. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); German Cancer Aid, Federal Ministry of Education and Research (Germany); Dutch Ministry of Health, Welfare and Sports, Dutch Prevention Funds, LK Research Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (the Netherlands); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skane and Västerbotten (Sweden); Cancer Research UK, Medical Research Council (UK).

ACKNOWLEDGEMENT

We thank the EPIC participants in this study.

Declaration of personal interests: None

Declaration of funding interests: This study was funded by The Sir Halley Stewart Trust, Crohn’s and Colitis UK and The NHS Executive Eastern Region. SSMC is supported by an NIHR clinical lectureship. The coordination project: overall evaluation of results.

European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997; 26(Suppl. 1): S26–36.

REFERENCES

1. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119–24.
2. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066–78.
3. Ananthakrishnan AN. Environmental triggers for inflammatory bowel disease. Curr Gastroenterol Rep 2013; 15: 302.
4. Fritsche K. Fatty acids as modulators of the immune response. Anna Rev Nutr 2006; 26: 45–73.
5. Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ, NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol 2003; 284: L84–9.
6. Yaqoob P, Shaikh SR. The nutritional and clinical significance of lipid rafts. Curr Opin Clin Nutr Metab Care 2010; 13: 156–66.
7. Goldman DW, Pickett WC, Goetel EJ. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun 1983; 117: 282–8.
8. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349–61.
9. Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005; 11: 154–63.
10. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease. Gut 2013; PMID: 23828881 [Epub ahead of print].
11. Levy BD. Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airways Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways. Front Immunol 2012; 3: 390.
12. Serini S, Bizzarro A, Piccioni E, et al. EPA and DHA differentially affect in vitro inflammatory cytokine release by peripheral blood mononuclear cells from Alzheimer’s patients. Curr Alzheimer Res 2012; 9: 913–23.
13. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002; 5(6B): 1113–24.
14. Chan SS, Luben R, Olsen A, et al. Body Mass Index and the Risk for Crohn’s Disease and Ulcerative Colitis: Data From a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol 2013; 108: 575–82.
15. Kaaks R, Slimani N, Riboli E. Pilot phase studies on the accuracy of dietary intake measurements in the EPIC project: overall evaluation of results. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997; 26(Suppl. 1): S26–36.
16. Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. Br J Nutr 2002; 88: 355–63.
17. Salem N Jr, Pawlosky R, Wegher B, Hibilihn J. In vivo conversion of linoleic acid to arachidonic acid in human adults. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 407–10.
18. Bartoli R, Fernandez-Banares F, Navarro E, et al. Effect of olive oil on early and late events of colon carcinogenesis in rats: modulation of arachidonic acid metabolism and local prostaglandin E(2) synthesis. Gut 2000; 46: 191–9.
19. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology 2012; 142: 482–9.
20. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A 1983; 80: 3581–4.
21. Rao GH, Radha E, White JG. Effect of docosahexaenoic acid (DHA) on arachidonic acid metabolism and...
platelet function. Biochem Biophys Res Commun 1983; 117: 549–55.

22. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171–6.

23. Hommes DW, Meenan J, de Haas M, et al. Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut 1996; 38: 564–7.

24. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005; 102: 7671–6.

25. Weylandt KH, Chiu CY, Gomolka B, Waechter SF, Wiedenmann B. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat 2012; 97: 73–82.

26. Depner CM, Philbrick KA, Jump DB. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. J Nutr 2013; 143: 315–23.

27. Watanabe S, Tsuneyama K. Eicosapentaenoic acid attenuates hepatic accumulation of cholesterol esters but aggravates liver injury and inflammation in mice fed a cholate-supplemented high-fat diet. J Toxicol Sci 2013; 38: 379–90.

28. Rodriguez-Lagunas MJ, Ferrer R, Moreno JJ. Effect of eicosapentaenoic acid-derived prostaglandin E3 on intestinal epithelial barrier function. Prostaglandins Leukot Essent Fatty Acids 2013; 88: 339–45.

29. Tjonneland A, Overvad K, Bergmann MM, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut 2009; 58: 1606–11.

30. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996; 334: 1557–60.

31. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008; 299: 1690–7.

32. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane database of systematic reviews 2009; 1: CD006320.

33. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690–7.

34. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2013; 63: 423–32.

35. Bates B, Bates C, Prentice A, Swan G (eds). National Diet and Nutrition Survey. Headline results from Years 1 and 2 (combined) of the Rolling Programme (2008/09 – 2009/10). Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_130728.

36. Bingham SA, Gill C, Welch A, et al. Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers. Int J Epidemiol 1997; 26 (Suppl. 1): S137–51.

37. Goldbohm RA, van’t Veer P, van den Brandt PA, et al. Reproducibility of a food frequency questionnaire and stability of dietary habits determined from five annually repeated measurements. Eur J Clin Nutr 1995; 49: 420–9.